TreAura

TreAura is a clinical-stage biotechnology company dedicated to developing and commercializing innovative therapies for patients with rare metabolic diseases. The company's lead program, TA-101 (pegzilarginase), is a recombinant human arginase 1 enzyme replacement therapy designed to lower elevated arginine levels in patients with Arginase 1 Deficiency (ARG1-D). TreAura was established in 2023 by former leadership from Aeglea BioTherapeutics to advance the development of pegzilarginase in the United States and other key markets. The company operates in strategic partnership with Immedica Pharma, which holds the global rights to the asset. TreAura is currently focused on the regulatory resubmission process for TA-101, aiming to address the significant unmet medical need in the ARG1-D community.